3.9 Article

STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data

Journal

FUTURE SCIENCE OA
Volume 7, Issue 3, Pages -

Publisher

FUTURE SCI LTD
DOI: 10.2144/fsoa-2020-0130

Keywords

lung cancer; non-small-cell lung cancer (NSCLC); radical resection (RR); serum thymidine kinase 1 protein (STK1p); survival; thymidine kinase 1 (TK1)

Funding

  1. Major Special Funds of National Science and Technology in China: 'Innovate New Drugs for the Prevention of Major Diseases and Establish Demonstrative Technology Platform for International Standardized Clinical Evaluation [2018ZX09201-013]
  2. Science and Technology Projects of JiangSu city [SS201631]
  3. Affiliated Hospital of Suzhou University, JiangSu, China
  4. Peking 301 General Hospital, China
  5. Medicine Department, Shenzhen Precision Medicine Institute, Shenzhen, China

Ask authors/readers for more resources

The prospective study evaluated the prognostic value of serum thymidine kinase 1 concentration in non-small-cell lung carcinoma patients. Results showed that elevated STK1p values were associated with worse overall survival, especially in early/middle stages, and STK1p could be an independent prognostic factor for favorable overall survival in NSCLC patients.
Aim: A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs). Patients & methods: The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017. Results: Kaplan-Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS. Conclusion: STK1p is helpful in predicting OS of early/middle stages (I-IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs. Lay abstract: Lung cancer is one of the most common types of tumors, with a high mortality rate. We investigate if thymidine kinase 1 in serum (STK1p) is a reliable prognostic marker for survival in non-small-cell lung carcinoma. We recruited 127 patients in this study. STK1p level was determined using a high-sensitive chemiluminescent dot blot assay. Patients with elevated STK1p values had worse overall survival, especially patients in the early/middle cancer stages. Analysis showed that STK1p is an independent prognostic factors for overall survival. We concluded that STK1p is helpful predicting the efficacy of treatment in non-small-cell lung carcinoma for those in the early/middle stages.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available